Skip to main content
Pulike Biological Engineering,Inc. logo

Pulike Biological Engineering,Inc. — Investor Relations & Filings

Ticker · 603566 ISIN · CNE1000025N0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,082 across all filing types
Latest filing 2026-06-08 Notice of Dividend Amou…
Country CN China
Listing Shanghai Stock Exchange 603566

About Pulike Biological Engineering,Inc.

http://en.pulike.com.cn/

Pulike Biological Engineering, Inc. specializes in the research, development, and production of veterinary biological products and pharmaceutical preparations. The company focuses on animal disease prevention through the manufacture of high-end vaccines, diagnostic reagents, and veterinary medicines. Its product range primarily serves the swine and poultry sectors, featuring advanced biologicals such as genetically engineered vaccines and synthetic peptide products. Pulike maintains a strong emphasis on technological innovation, utilizing national-level research platforms to develop solutions for complex animal health challenges. The company’s core activities encompass the entire value chain from basic biotechnology research to the commercialization of veterinary health solutions, aiming to improve livestock productivity and biosecurity.

Recent filings

Filing Released Lang Actions
普莱柯2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 90% confidence The document is a formal dividend distribution announcement by 普莱柯生物工程股份有限公司 for the 2025 fiscal year, specifying the cash dividend per share, record/ex‐dividend dates, payment dates, tax treatments, and implementation procedures. This clearly matches a Notice of Dividend Amount rather than a report, management discussion, or proxy materials.
2026-06-08 Chinese
普莱柯关于获得新兽药注册证书的公告
Regulatory Filings Classification · 78% confidence The document is a corporate announcement (“公告”) regarding the approval of a new veterinary drug registration certificate by the Ministry of Agriculture. It contains no financial data, no board or senior management changes, no earnings or dividend information, and no detailed report or presentation. This is a regulatory update/filing that doesn’t fit into a more specific category, so it should be classified as a general regulatory announcement (RNS).
2026-06-05 Chinese
普莱柯2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an official announcement of the 2025 annual shareholders meeting resolutions, showing detailed voting results (votes for, against, abstentions) on each proposal. It is not the meeting materials themselves, nor a full annual report or financial statements, but rather the formal declaration of voting outcomes at the general meeting. This fits the Definition for Declaration of Voting Results & Voting Rights Announcements (Code: DVA).
2026-05-21 Chinese
北京德恒律师事务所关于普莱柯生物工程股份有限公司2025年年度股东会的法律意见
Regulatory Filings Classification · 88% confidence The document is a legal opinion letter from Beijing DeHeng Law Offices regarding the legality of the company’s 2025 annual shareholders’ meeting, attesting to the procedural compliance, participants, and vote tallies. It does not itself constitute an annual report, proxy statement, voting results announcement issued by the company, or any other specified corporate report type. Instead, it is an attestation/certification letter, which under the certification rule should be classified as a general regulatory filing (RNS).
2026-05-21 Chinese
普莱柯2025年年度股东会会议资料
AGM Information Classification · 92% confidence The document is titled “2025年年度股东会会议资料” and contains detailed agenda, meeting procedures, and proposals for the company’s 2025 Annual General Meeting. It does not itself present the full annual report but serves as the materials provided to shareholders at the AGM. This matches the definition of AGM Information (Code: AGM-R).
2026-05-13 Chinese
普莱柯关于召开2025年第三季度业绩说明会的公告
Investor Presentation Classification · 90% confidence The document is an announcement about the scheduling and details of a 2025 third quarter earnings explanation meeting (业绩说明会) for investors. It mentions the date and time of the meeting, the format (online interactive session), and the participation details. It references the prior release of the 2025 third quarter report but does not contain any financial data or analysis itself. The document is short (1395 characters) and serves to inform investors about the upcoming earnings call rather than presenting the earnings results. Therefore, it is best classified as a Call Transcript announcement or related to earnings communication. However, since it is an announcement of the earnings explanation meeting and not the transcript or the earnings release itself, the closest fitting category is Investor Presentation (IP), which covers detailed presentations for investors focusing on financials and strategy. Given the interactive nature and focus on discussing quarterly results, IP is appropriate. Confidence is high due to clear meeting details and purpose.
2025-10-30 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.